Picture
 

Gilbert Melendez Ends Drug Suspension Against Edson Barboza At UFC on FOX 20

Written by Tom Ngo
May 5th, 2016
Share on Facebook0Google+0Tweet about this on Twitter

UFC Gilbert Melendez

Former lightweight top contender Gilbert Melendez (pictured) ends his yearlong testosterone suspension against Edson Barboza at UFC on FOX 20.

The shootout was announced by the UFC via Twitter.

Melendez tested positive for exogenous origin of testosterone metabolites following lat June’s split decision defeat to Eddie Alvarez at UFC 188. Melendez never admitted to taking any banned substances, but accepted responsibility for not knowing what he was putting in his system.

You know, the typical response an athlete gives when they get busted for using performance-enhancing drugs…

“El Nino” was lucky he didn’t test positive one month later when the UFC’s revamped drug testing program kicking in. He would have been banned for two years if the bout had taken place just two weeks later.

Melendez has dropped three of his past four fights, including two straight. Two of those losses were for the UFC lightweight title, first against then-champion Benson Henderson in 2013 and the other against then-champ Anthony Pettis a year later.

Speaking of Pettis, Barboza schooled “Showtime” last month at UFC 197 for a lopsided unanimous decision win. The Brazilian has shown flashes of brilliance throughout his UFC career, but is searching for some consistency having alternated between wins and losses over his past five outings.

The July 23 takes place inside Philips Arena in Atlanta. FOX broadcasts the main card live.

Here is the show’s current roster:

Luis Henrique vs. Dmitry Smolyakov

Kailin Curran vs. Felice Herrig

Tony Martin vs. Michel Prazeres

Frankie Saenz vs. Eddie Wineland

James Moontasri vs. Alex Oliveira

George Sullivan vs. Hector Urbina

Ryan LaFlare vs. Alexander Yakovlev

Edson Barboza vs. Gilbert Melendez

Anthony Johnson vs. Glover Teixeira

Holly Holm vs. Valentina Shevchenko

Don’t forget to follow @5thRound on Twitter, Facebook and Google+!



COMMENTS